Emactuzumab is under clinical development by SynOx Therapeutics and currently in Phase III for Tenosynovial Giant Cell Tumor. According to GlobalData, Phase III drugs for Tenosynovial Giant Cell Tumor have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Emactuzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Emactuzumab (RG-7155, RO5509554) is under development for the treatment of solid tumors like metastatic pancreatic ductal adenocarcinoma, metastatic ovarian cancer, metastatic triple negative breast cancer, bladder cancer, gastric cancer, soft tissue sarcoma, colorectal cancer, pancreatic cancer, melanoma or malignant mesothelioma, tenosynovial giant cell tumor, pigmented villonodular synovitis and relapsed or refractory platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer clear cell adenocarcinoma, endometrioid adenocarcinoma, malignant Brenner's tumor, mixed epithelial carcinoma, mucinous adenocarcinoma, serous adenocarcinoma, transitional cell carcinoma, undifferentiated carcinoma. The drug candidate is administered through intravenous route. It is a new molecular entity (NME). RG7155 acts on targeting colony stimulating factor-1 receptor (CSF-1R). It was also under development for treatment of relapsed or refractory follicular lymphoma.
SynOx Therapeutics overview
SynOx Therapeutics (SynOx) is a biopharmaceutical company. It develops emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (TGCT), also known as pigmented villonodular synovitis (PVNS) and other indications. SynOx is headquartered in Dublin, Ireland.
For a complete picture of Emactuzumab’s drug-specific PTSR and LoA scores, buy the report here.